What we do
Our vision is to provide products that deliver the most complete and actionable genomic data.
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.
Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. Prior to 10x Genomics, Serge was VP of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was Founding Architect and Director of R&D at 23andMe.
There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard University.
Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.
Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.
Prior to Merck, Dr. Mammen led R&D at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).
Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.
[PLEASANTON, CA] March 17, 2016 — 10x Genomics, a company focused on improving and broadening the application of genomic information today announced the close of a $55 million Series C financing. The financing round was led by Fidelity Management & Research Company and included additional new investors Softbank and JS Capital Management LLC, alongside founding investors Venrock, Foresite Capital, and Paladin Capital. The Series C financing will accelerate 10x marketing and sales efforts in support of its GemCode™ and Chromium™ products revolutionizing genome sequencing, while fueling innovative future product development. READ MORE…
We invite investors to get a hold of us at IR@10xgenomics.com.
Join our expanding network of global distributors!
Monash Enterprise Centre
5a Hartnett Close
Mulgrave, Victoria 3170
1808, 79 Nonhyeon-ro,
Seoul, 06775 Korea
Tel: +82 2 575 6227
Fax: +82 2 575 6228
47 Ayer Rajah Crescent #03-12
Republic of Singapore 139947
Tel: +65 6571 0888
Fax: +65 6571 0868
Kawakoshi Bldg. 3-9-2
Midori, Sumida-ku Tokyo 130-0021
Tel: +81 (0)3 5625 9711
Fax: +81 (0)3 3634 6333
Office 1610, Concord Tower
Dubai Media City
P.O. Box 500392
Dubai – UAE Tel: +971 4 375 2-44
Fax: +971 4 429 1376